(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.13%) $0.800
(-0.32%) $91.87
3 days till quarter result
(bmo 2024-04-30)
Expected move: +/- 10.97%
@ $14.92
Issued: 14 Feb 2024 @ 15:55
Return: -5.23%
Previous signal: Feb 14 - 14:11
Previous signal:
Return: 1.53 %
Live Chart Being Loaded With Signals
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments...
Stats | |
---|---|
Today's Volume | 787 712 |
Average Volume | 905 165 |
Market Cap | 1.81B |
EPS | $0 ( 2024-02-20 ) |
Next earnings date | ( $-0.0300 ) 2024-04-30 |
Last Dividend | $0.400 ( 2020-12-17 ) |
Next Dividend | $0 ( N/A ) |
P/E | -20.20 |
ATR14 | $0.0180 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Tetrault Lynn A. | Sell | 6 112 | Common Stock |
2024-02-23 | Stone Warren | Buy | 42 344 | Stock Option (Right to Buy) |
2024-02-23 | Stone Warren | Buy | 25 330 | Performance Stock Unit |
2024-02-23 | Stone Warren | Buy | 25 329 | Restricted Stock Unit |
2024-02-23 | Olivo Alicia C | Buy | 42 344 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
92.16 |
Last 88 transactions |
Buy: 4 083 000 | Sell: 279 791 |
Volume Correlation
Neogenomics Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Neogenomics Inc Correlation - Currency/Commodity
Neogenomics Inc Financials
Annual | 2023 |
Revenue: | $591.64M |
Gross Profit: | $244.60M (41.34 %) |
EPS: | $-0.700 |
FY | 2023 |
Revenue: | $591.64M |
Gross Profit: | $244.60M (41.34 %) |
EPS: | $-0.700 |
FY | 2022 |
Revenue: | $509.73M |
Gross Profit: | $187.90M (36.86 %) |
EPS: | $-1.160 |
FY | 2021 |
Revenue: | $484.33M |
Gross Profit: | $187.06M (38.62 %) |
EPS: | $-0.0700 |
Financial Reports:
No articles found.
Neogenomics Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.400 | 2020-12-17 |
Last Dividend | $0.400 | 2020-12-17 |
Next Dividend | $0 | N/A |
Payout Date | 2020-12-30 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.400 | -- |
Avg. Dividend % Per Year | 0.09% | -- |
Score | 0.32 | -- |
Div. Sustainability Score | 3.17 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.927 | -- |
Year | Amount | Yield |
---|---|---|
2020 | $0.400 | 1.38% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.149 | 1.500 | -2.97 | -4.46 | [0 - 0.5] |
returnOnAssetsTTM | -0.0523 | 1.200 | -1.744 | -2.09 | [0 - 0.3] |
returnOnEquityTTM | -0.0921 | 1.500 | -2.13 | -3.20 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 6.20 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.67 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 3.56 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.364 | -1.500 | 3.94 | -5.90 | [0 - 0.6] |
interestCoverageTTM | 20.01 | 1.000 | 3.70 | 3.70 | [3 - 30] |
operatingCashFlowPerShareTTM | -0.0155 | 2.00 | -0.00517 | -0.0103 | [0 - 30] |
freeCashFlowPerShareTTM | -0.244 | 2.00 | -0.122 | -0.244 | [0 - 20] |
debtEquityRatioTTM | 0.650 | -1.500 | 7.40 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.413 | 1.000 | 6.44 | 6.44 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.174 | 1.000 | -5.48 | -5.48 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -0.00319 | 1.000 | -1.129 | -1.129 | [0.2 - 2] |
assetTurnoverTTM | 0.352 | 0.800 | -0.987 | -0.790 | [0.5 - 2] |
Total Score | 3.17 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -19.83 | 1.000 | -2.10 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0921 | 2.50 | -1.372 | -3.20 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.244 | 2.00 | -0.0813 | -0.244 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -0.0155 | 2.00 | -0.00517 | -0.0103 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.00944 | 1.500 | -3.27 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.00330 | 1.000 | -2.58 | 0 | [0.1 - 0.5] |
Total Score | -1.320 |
Neogenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators